Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST) ... a new design for an atomic clock that ... a microcomb. , The microcomb clock, featured on ... new journal Optica ,* is the first ... its accurate conversion of optical frequencies to lower ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 CTD Holdings, ... the pharmaceutical, medical device, cosmetics, and other markets, announced ... with a group of qualified private investors led by ... , The transaction involved the signing of ... 1,725,000 shares of Common Stock at a price per ...
(Date:7/22/2014)... July 22, 2014 OHAUS Corporation, ... and mechanical balances and scales, proudly announces its ... won Laboratory Equipment magazine’s 2014 “Readers' Choice” Award ... consecutive year the Explorer was voted the best ... Readers’ Choice Awards celebrates “excellence in product design ...
(Date:7/22/2014)... and SHENZHEN, China ... Solutions Co., LTD, (BGI Tech), a subsidiary of ... the global launch of a new human whole ... platform. This newly offered service includes in-depth bioinformatics ... reduced prices until December 31, 2014. ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... of nanomaterials for application in devices may be addressed ... conducted by scientists from the National University of Singapore ... and low cost technique involving a focused laser beam, ... Haur from the Department of Physics at the NUS ... different types of materials can be controlled and modified, ...
(Date:7/22/2014)... milk helps make their bones strong or that fish is food ... if something is good for us, it must surely taste bad? ... Research , when children hear about the benefits of healthy food, ... food is presented to children as making them strong or as ... read or count, they would conclude the food is not as ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... 2010): Today, the Association for Molecular Pathology (AMP) submitted written ... the National Institutes of Health (NIH) for its Genetic Test ... to formulate a comprehensive response to the RFI. "With ... setting, AMP is able to inform the NIH on the ...
... While pundits write obituaries for the 2010 climate bill, ... the world. We are losing species and ecosystems are unraveling ... We need new tools and strategies to deal with these ... to announce the launch of their new Climate Adaptation Knowledge ...
... PHILADELPHIAIn 1824, three years before he began to publish his ... Audubon (1785-1851), the eminent artist of American birds and animals, ... the design for a New Jersey bank note. Although the ... in two separate diary entries, no one has ever been ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2CAKE offers way forward for climate change adaptation 2Discovered: Audubon's first engraving of a bird 2
...
... Forma Incubated Orbital Shakers combine high ... performance and ease of use. The ... allowing the unit to run at ... The unit's class-leading temperature range is ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... have the durability to run ... and the uniformity and contamination ... applications. Heavily built with ... stackers are designed for ease ...
Biology Products: